Ginaton
Phase 3Small molecule
Ginaton is one of 83 small molecule programs targeting Hearing Loss. It is currently in Phase 3.
4
Indications
4
Total Trials
2
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
116 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Tnkase
RochePhase 3
Ozempic
Novo NordiskPhase 3
Reminyl
WWim Janssens
Phase 3
Atorvastatin Calcium
Merck & Co.Phase 3
Intravenous Thrombolysis
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
Aggrastat
MMedicure
Phase 3
Ginaton
PPeking University People's Hospital
Phase 3
Rhtnk-Tpa
CCSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Phase 3
SP-8203
SShin Poong Pharmaceutical Co. Ltd.
Phase 3
Y-6
BBeijing Tiantan Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ischemic stroke1 trial
Efficacy of Diterpene Ginkgolides Meglumine Injection in Elderly Patients With Ischemic Stroke
Completed·—·N/A·NCT05169450·998 enrolled
ISS1 trial
The Effect of PAP on ISSHL Comorbided With OSA
Recruiting·—·Phase 4·NCT04192656·102 enrolled
Diabetic Retinopathy1 trial
Efficacy and Safety of Ginkgo Biloba Extract EGb761® in Patients With Diabetic Retinopathy
Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT07236645·200 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ginaton. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details